FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087006383> ?p ?o ?g. }

• W3087006383 endingPage "e1315" @default.
• W3087006383 startingPage "e1305" @default.
• W3087006383 abstract "<h2>Summary</h2><h3>Background</h3> Community-based delivery of antiretroviral therapy (ART) for HIV, including ART initiation, clinical and laboratory monitoring, and refills, could reduce barriers to treatment and improve viral suppression, reducing the gap in access to care for individuals who have detectable HIV viral load, including men who are less likely than women to be virally suppressed. We aimed to test the effect of community-based ART delivery on viral suppression among people living with HIV not on ART. <h3>Methods</h3> We did a household-randomised, unblinded trial (DO ART) of delivery of ART in the community compared with the clinic in rural and peri-urban settings in KwaZulu-Natal, South Africa and the Sheema District, Uganda. After community-based HIV testing, people living with HIV were randomly assigned (1:1:1) with mobile phone software to community-based ART initiation with quarterly monitoring and ART refills through mobile vans; ART initiation at the clinic followed by mobile van monitoring and refills (hybrid approach); or standard clinic ART initiation and refills. The primary outcome was HIV viral suppression at 12 months. If the difference in viral suppression was not superior between study groups, an a-priori test for non-inferiority was done to test for a relative risk (RR) of more than 0·95. The cost per person virally suppressed was a co-primary outcome of the study. This study is registered with ClinicalTrials.gov, NCT02929992. <h3>Findings</h3> Between May 26, 2016, and March 28, 2019, of 2479 assessed for eligibility, 1315 people living with HIV and not on ART with detectable viral load at baseline were randomly assigned; 666 (51%) were men. Retention at the month 12 visit was 95% (n=1253). At 12 months, community-based ART increased viral suppression compared with the clinic group (306 [74%] <i>vs</i> 269 [63%], RR 1·18, 95% CI 1·07–1·29; p_superiority=0·0005) and the hybrid approach was non-inferior (282 [68%] <i>vs</i> 269 [63%], RR 1·08, 0·98–1·19; p_{non-inferiority}=0·0049). Community-based ART increased viral suppression among men (73%, RR 1·34, 95% CI 1·16–1·55; p_superiority<0·0001) as did the hybrid approach (66%, RR 1·19, 1·02–1·40; p_superiority=0·026), compared with clinic-based ART (54%). Viral suppression was similar for men (n=156 [73%]) and women (n=150 [75%]) in the community-based ART group. With efficient scale-up, community-based ART could cost US$275–452 per person reaching viral suppression. Community-based ART was considered safe, with few adverse events. <h3>Interpretation</h3> In high and medium HIV prevalence settings in South Africa and Uganda, community-based delivery of ART significantly increased viral suppression compared with clinic-based ART, particularly among men, eliminating disparities in viral suppression by gender. Community-based ART should be implemented and evaluated in different contexts for people with detectable viral load. <h3>Funding</h3> The Bill & Melinda Gates Foundation; the University of Washington and Fred Hutch Center for AIDS Research; the Wellcome Trust; the University of Washington Royalty Research Fund; and the University of Washington King K Holmes Endowed Professorship in STDs and AIDS." @default.
• W3087006383 created "2020-09-25" @default.
• W3087006383 creator A5001591720 @default.
• W3087006383 creator A5005065579 @default.
• W3087006383 creator A5008235594 @default.
• W3087006383 creator A5010100221 @default.
• W3087006383 creator A5013103542 @default.
• W3087006383 creator A5017146733 @default.
• W3087006383 creator A5020291656 @default.
• W3087006383 creator A5023423367 @default.
• W3087006383 creator A5026481326 @default.
• W3087006383 creator A5039461221 @default.
• W3087006383 creator A5043916447 @default.
• W3087006383 creator A5046685365 @default.
• W3087006383 creator A5058436429 @default.
• W3087006383 creator A5058600002 @default.
• W3087006383 creator A5061429355 @default.
• W3087006383 creator A5061513042 @default.
• W3087006383 creator A5064486492 @default.
• W3087006383 creator A5066722692 @default.
• W3087006383 creator A5068466674 @default.
• W3087006383 creator A5074151617 @default.
• W3087006383 creator A5074982599 @default.
• W3087006383 creator A5079205032 @default.
• W3087006383 creator A5081141710 @default.
• W3087006383 creator A5090773831 @default.
• W3087006383 date "2020-10-01" @default.
• W3087006383 modified "2023-10-17" @default.
• W3087006383 title "Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial" @default.
• W3087006383 cites W1986118563 @default.
• W3087006383 cites W1994773141 @default.
• W3087006383 cites W2029558670 @default.
• W3087006383 cites W2055868383 @default.
• W3087006383 cites W2069596315 @default.
• W3087006383 cites W2100430786 @default.
• W3087006383 cites W2114623877 @default.
• W3087006383 cites W2128478603 @default.
• W3087006383 cites W2143028771 @default.
• W3087006383 cites W2149860264 @default.
• W3087006383 cites W2152505869 @default.
• W3087006383 cites W2159899509 @default.
• W3087006383 cites W2406695479 @default.
• W3087006383 cites W2529978077 @default.
• W3087006383 cites W2560390059 @default.
• W3087006383 cites W2569446737 @default.
• W3087006383 cites W2746415643 @default.
• W3087006383 cites W2757843708 @default.
• W3087006383 cites W2775758586 @default.
• W3087006383 cites W2884876183 @default.
• W3087006383 cites W2887383763 @default.
• W3087006383 cites W2888116517 @default.
• W3087006383 cites W2890077055 @default.
• W3087006383 cites W2892986301 @default.
• W3087006383 cites W2899516169 @default.
• W3087006383 cites W2915166708 @default.
• W3087006383 cites W2958150136 @default.
• W3087006383 cites W2961360820 @default.
• W3087006383 cites W2963426746 @default.
• W3087006383 doi "https://doi.org/10.1016/s2214-109x(20)30313-2" @default.
• W3087006383 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7527697" @default.
• W3087006383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32971053" @default.
• W3087006383 hasPublicationYear "2020" @default.
• W3087006383 type Work @default.
• W3087006383 sameAs 3087006383 @default.
• W3087006383 citedByCount "66" @default.
• W3087006383 countsByYear W30870063832020 @default.
• W3087006383 countsByYear W30870063832021 @default.
• W3087006383 countsByYear W30870063832022 @default.
• W3087006383 countsByYear W30870063832023 @default.
• W3087006383 crossrefType "journal-article" @default.
• W3087006383 hasAuthorship W3087006383A5001591720 @default.
• W3087006383 hasAuthorship W3087006383A5005065579 @default.
• W3087006383 hasAuthorship W3087006383A5008235594 @default.
• W3087006383 hasAuthorship W3087006383A5010100221 @default.
• W3087006383 hasAuthorship W3087006383A5013103542 @default.
• W3087006383 hasAuthorship W3087006383A5017146733 @default.
• W3087006383 hasAuthorship W3087006383A5020291656 @default.
• W3087006383 hasAuthorship W3087006383A5023423367 @default.
• W3087006383 hasAuthorship W3087006383A5026481326 @default.
• W3087006383 hasAuthorship W3087006383A5039461221 @default.
• W3087006383 hasAuthorship W3087006383A5043916447 @default.
• W3087006383 hasAuthorship W3087006383A5046685365 @default.
• W3087006383 hasAuthorship W3087006383A5058436429 @default.
• W3087006383 hasAuthorship W3087006383A5058600002 @default.
• W3087006383 hasAuthorship W3087006383A5061429355 @default.
• W3087006383 hasAuthorship W3087006383A5061513042 @default.
• W3087006383 hasAuthorship W3087006383A5064486492 @default.
• W3087006383 hasAuthorship W3087006383A5066722692 @default.
• W3087006383 hasAuthorship W3087006383A5068466674 @default.
• W3087006383 hasAuthorship W3087006383A5074151617 @default.
• W3087006383 hasAuthorship W3087006383A5074982599 @default.
• W3087006383 hasAuthorship W3087006383A5079205032 @default.
• W3087006383 hasAuthorship W3087006383A5081141710 @default.
• W3087006383 hasAuthorship W3087006383A5090773831 @default.
• W3087006383 hasBestOaLocation W30870063831 @default.
• W3087006383 hasConcept C126322002 @default.
• W3087006383 hasConcept C142462285 @default.
• W3087006383 hasConcept C168563851 @default.

• next